Literature DB >> 9873103

Larynx preservation trials: a critical appraisal.

A A Forastiere1.   

Abstract

Controlled trials testing the concept of laryngeal preservation for patients with locally advanced stage III and IV cancers of the larynx or hypopharynx were initiated in the mid-1980s. Three randomized trials, evaluating the same cisplatin plus 5-fluorouracil induction chemotherapy regimen and conventional radiotherapy compared with surgery and radiotherapy, have been completed, and the results of two are published. In addition, a meta-analysis of these three trials was completed. The studies are critically reviewed. Conclusions from these trials are that the induction approach is feasible; local and regional control are not improved, whereas distant metastases are delayed; there is no evidence of a difference in overall survival; and of the patients alive at 3 and 5 years, a functional larynx can be preserved in 67% and 58%; there are not enough data to know if there are differences in outcome by subsite. Several unanswered questions are being addressed in phase III trials. These include defining the precise contribution of chemotherapy by comparing induction chemotherapy and radiotherapy to treatment with radiotherapy alone; determining if elective neck dissection for patients with N2N3 neck disease would improve survival; and determining whether local control can be improved by using concomitant or alternating chemotherapy and radiotherapy.

Entities:  

Mesh:

Year:  1998        PMID: 9873103     DOI: 10.1016/s1053-4296(98)80023-4

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  2 in total

Review 1.  Altered fractionation in the treatment of head and neck cancer.

Authors:  K S Hu; L B Harrison
Journal:  Curr Oncol Rep       Date:  1999       Impact factor: 5.075

2.  Clinicopathological factors influencing the outcomes of surgical treatment in patients with T4a hypopharyngeal cancer.

Authors:  Sang-Yeon Kim; Young-Soo Rho; Eun-Chang Choi; Min-Sik Kim; Joo-Hyun Woo; Dong Hoon Lee; Eun Jae Chung; Min Woo Park; Da-Hee Kim; Young-Hoon Joo
Journal:  BMC Cancer       Date:  2017-12-29       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.